NCT07195864View on ClinicalTrials.gov

"Retrospective Chart Review of Patients With Acanthamoeba Keratitis Who Have Received 0.8 mg/mL Polihexanide as Part of the Medicines in Special Situations (Medicamentos en Situaciones Especiales) Program in Spain."

Not yet recruitingOBSERVATIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

June 30, 2026

Conditions
Acanthamoeba Keratitis
Interventions
DRUG

PHMB 0.08%

The study population for this study is patients diagnosed with AK treated with 0.8 mg/ml polihexanide as part of the Spanish Medicines in Special Situations program.

All Listed Sponsors
lead

SIFI SpA

INDUSTRY

NCT07195864 - "Retrospective Chart Review of Patients With Acanthamoeba Keratitis Who Have Received 0.8 mg/mL Polihexanide as Part of the Medicines in Special Situations (Medicamentos en Situaciones Especiales) Program in Spain." | Biotech Hunter | Biotech Hunter